Lisinopril News and Research

RSS

Blood pressure drug associated with lower risk of Alzheimer's disease in Black patients

Considering how patients from different ethnic groups respond to the same drug could be crucial to finding new Alzheimer's disease treatments – a disorder the Alzheimer's Association previously deemed a "silent epidemic" among Black adults.

4 Nov 2022

Drug combinations may help to slow the progression of diabetic kidney disease

A mouse study led by Washington University School of Medicine in St. Louis suggests that combining SGLT2 inhibitors — a newer class of diabetes medications that lowers blood sugar — with older diabetes drugs may help to slow the progression of diabetic kidney disease.

15 Jun 2022

The latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2

A recent review discusses the engineering versatility of polymeric nanoparticles - making a good therapeutic alternative against coronavirus diseases.

19 Jan 2022

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

Researchers have screened several compounds that could show the ability to inhibit SARS-CoV-2.

10 Dec 2021

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

25 Oct 2021

Two types of blood pressure drugs provide equal benefits, but side effects differ

People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.

26 Jul 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Key China COVID-19 study produced results that influenced subsequent research on coronavirus

Early in the onset of the COVID-19 pandemic, a small study in China produced results that influenced subsequent research on the virus.

18 Sep 2020

Computational models screen for coronaviruses likely to infect humans

The researchers from Rochester Institute of Technology and the Hauptmann-Woodward Medical Research Institute produced models of the receptor-binding domain (RBD) found on outbreak strains of betacoronaviruses and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

14 Sep 2020

Antihypertensive drugs may protect against COVID-19 in heart patients

Common drugs used in high blood pressure, heart failure, and diabetic patients with kidney damage, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), could be protective in patients with COVID-19.

31 Mar 2020

Antihypertensive drug associated with lower risk of gout

Affecting more than 7 million adults in the United States, gout is characterized by a sudden onset of pain, swelling and stiffness in the joints and caused by the formation of urate crystal in small spaces between joints that builds up when high amounts of uric acid circulate in the blood.

27 Jan 2020

Study finds drug interactions in ER's are common but could be prevented

In a recent Rutgers study, 38 percent of patients discharged from the emergency department had at least one drug interaction resulting from a newly prescribed medicine.

26 Feb 2019

Researchers find wide price variability in generic heart failure drugs

New research from Saint Louis University finds that the prices for commonly used generic heart failure drugs varies widely.

16 Nov 2016

Lisinopril oral solution approved for treatment of hypertension in children and adults

Silvergate Pharmaceuticals, Inc., leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Qbrelis (Lisinopril) Oral Solution, the first and only FDA-approved Lisinopril oral solution.

30 Jul 2016

Pharmacotherapy reduces conduction system disease risk

Lisinopril therapy significantly reduces incident conduction system disease, indicates a post-hoc analysis of ALLHAT data.

28 Jun 2016

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.

17 Nov 2014

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

8 Sep 2014

Implementation of large-scale hypertension program linked with doubling of hypertension control rates

Implementation of a large-scale hypertension program that included evidence-based guidelines and development and sharing of performance metrics was associated with a near-doubling of hypertension control between 2001 and 2009, compared to only modest improvements in state and national control rates, according to a study in the August 21 issue of JAMA.

21 Aug 2013

Controlling blood pressure and cholesterol may reduce risk of heart attack or stroke in diabetics

For people with diabetes, meeting the recommended guidelines for blood pressure and cholesterol is even more important than meeting the guidelines for blood sugar control in reducing the risk of heart attack or stroke, according to a new Kaiser Permanente study published today in the Journal of General Internal Medicine.

29 Jan 2013